Arcturus Therapeutics
ARCT
19 hedge funds and large institutions have $9.98M invested in Arcturus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
88% more capital invested
Capital invested by funds: $5.29M → $9.98M (+$4.69M)
2.64% more ownership
Funds ownership: 10.94% → 13.58% (+2.6%)
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$573K |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$328K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$312K |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$282K |
| 5 |
HCM
Highline Capital Management
New York
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$201K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$131K |
| 3 |
Morgan Stanley
New York
|
-$7.69K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7K |
| 5 |
BlackRock
New York
|
-$6.66K |
ARCT Hedge Fund Activity: Q1 2019 in Review
19 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2019, worth a combined $9.98M — up 88% from $5.29M a quarter earlier.
Fund positioning in ARCT was balanced in Q1 2019: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $573K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $201K sold.
- 19 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $9.98M of Arcturus Therapeutics stock for Q1 2019, up 88% quarter-over-quarter.
- 5 funds opened new Arcturus Therapeutics positions in Q1 2019 and 5 closed out, a net change of 0 holders.
- The largest Arcturus Therapeutics buyer in Q1 2019 was ARK Investment Management, an estimated $573K added.
- The largest Arcturus Therapeutics seller in Q1 2019 was Susquehanna International Group, an estimated $201K sold.
Based on aggregated 13F filings for Q1 2019.